Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation

Akari Therapeutics Plc

Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.
ADS unit purchase price: $0.87 plus $0.25–$0.3125 premium per tier; warrants exercisable at $0.87.
Series A warrants expire 1 year, Series B warrants expire 5 years from closing.
Chairman Dr. Hoyoung Huh, CEO Dr. Samir Patel, and all board members participating; $1M note terminated.
Proceeds for working capital; resale registration statement to be filed within 60 days of closing (expected March 5).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.